EA201491851A1 - COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - Google Patents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Info

Publication number
EA201491851A1
EA201491851A1 EA201491851A EA201491851A EA201491851A1 EA 201491851 A1 EA201491851 A1 EA 201491851A1 EA 201491851 A EA201491851 A EA 201491851A EA 201491851 A EA201491851 A EA 201491851A EA 201491851 A1 EA201491851 A1 EA 201491851A1
Authority
EA
Eurasian Patent Office
Prior art keywords
seq
antibodies
fragments
amino acid
alzheimer
Prior art date
Application number
EA201491851A
Other languages
Russian (ru)
Inventor
Нейл Р. Кэшман
Грант Маккларти
Original Assignee
Канджин Ю.С., Инкорпорейтед
Зе Юниверсити Оф Бритиш Колумбия
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Канджин Ю.С., Инкорпорейтед, Зе Юниверсити Оф Бритиш Колумбия filed Critical Канджин Ю.С., Инкорпорейтед
Publication of EA201491851A1 publication Critical patent/EA201491851A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Abstract

В изобретении предложен гипериммунный препарат, который содержит поликлональные антитела человека или фрагменты указанных антител, специфичные к циклическому пептиду, имеющему аминокислотную последовательность, которая содержит SNK. Циклический пептид может содержать аминокислотную последовательность GSNK (SEQ ID NO: 1), SNKG (SEQ ID NO: 2), GSNKG (SEQ ID NO: 3), CSNKG (SEQ ID NO: 4), CGSNKGC (SEQ ID NO: 5), CGSNKGG (SEQ ID NO: 6) или CCGSNKGC (SEQ ID NO: 7). Титр антител в указанном гипериммунном препарате может составлять от приблизительно 200 до приблизительно 400 единиц средней интенсивности флуоресценции. Согласно одному варианту реализации изобретения более чем приблизительно 80% антител в указанном гипериммунном препарате представляют собой IgG. Фрагменты указанных антител представляют собой Fab, F(ab'), scFv, связанный дисульфидными связями Fv или смеси указанных фрагментов.The invention provides a hyperimmune preparation that contains human polyclonal antibodies or fragments of these antibodies specific for a cyclic peptide having an amino acid sequence that contains SNK. The cyclic peptide may contain the amino acid sequence GSNK (SEQ ID NO: 1), SNKG (SEQ ID NO: 2), GSNKG (SEQ ID NO: 3), CSNKG (SEQ ID NO: 4), CGSNKGC (SEQ ID NO: 5) , CGSNKGG (SEQ ID NO: 6) or CCGSNKGC (SEQ ID NO: 7). The antibody titer in said hyperimmune preparation may be from about 200 to about 400 units of average fluorescence intensity. In one embodiment, more than approximately 80% of the antibodies in said hyperimmune preparation are IgG. Fragments of these antibodies are Fab, F (ab '), scFv linked by Fv disulfide bonds, or mixtures of these fragments.

EA201491851A 2011-11-10 2012-11-12 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE EA201491851A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161558430P 2011-11-10 2011-11-10
US201261589809P 2012-01-23 2012-01-23
US201213582308A 2012-08-31 2012-08-31
PCT/US2012/064722 WO2013071267A1 (en) 2011-11-10 2012-11-12 Compositions and methods for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
EA201491851A1 true EA201491851A1 (en) 2015-12-30

Family

ID=48290671

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491851A EA201491851A1 (en) 2011-11-10 2012-11-12 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Country Status (8)

Country Link
EP (1) EP2780082A4 (en)
CN (1) CN104093454A (en)
AU (1) AU2012335014A1 (en)
CA (1) CA2855669A1 (en)
EA (1) EA201491851A1 (en)
HK (1) HK1201771A1 (en)
SG (1) SG11201403272YA (en)
WO (1) WO2013071267A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011223456A1 (en) 2010-03-03 2012-10-18 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies
EP3102611A4 (en) * 2014-02-03 2017-08-23 Cangene Corporation Humanized beta-amyloid binding molecules and uses thereof
WO2016008047A1 (en) * 2014-07-14 2016-01-21 Cangene Corporation Cyclic peptide vaccination for treatment of amyloid beta-related disorders
CA2986431C (en) * 2015-05-18 2020-04-14 Synaptec Development Llc Galantamine clearance of amyloid.beta.
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
WO2017079834A1 (en) * 2015-11-09 2017-05-18 The University Of British Columbia Epitopes in amyloid beta and conformationally-selective antibodies thereto
EP3374379A4 (en) * 2015-11-09 2019-05-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
WO2017079835A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
US20180346534A1 (en) * 2015-11-09 2018-12-06 The University Of British Columbia C-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN112661828B (en) * 2021-01-15 2022-04-01 武汉大学 Antigen peptide of synapsin, antibody and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010002251A1 (en) * 2008-07-01 2010-01-07 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
AU2009330124A1 (en) * 2008-12-22 2011-07-14 Sloan-Kettering Institute For Cancer Research Coumarin-based compounds for the treatment of Alzheimer's disease and cancer
CN102859363A (en) * 2010-02-09 2013-01-02 百时美施贵宝公司 Immunoassay Standards And Measurement Of Clinical Biomarkers Using Intra-assay Calibration Standards
AU2011223456A1 (en) * 2010-03-03 2012-10-18 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies

Also Published As

Publication number Publication date
CA2855669A1 (en) 2013-05-16
SG11201403272YA (en) 2014-08-28
EP2780082A4 (en) 2015-08-05
EP2780082A1 (en) 2014-09-24
WO2013071267A1 (en) 2013-05-16
HK1201771A1 (en) 2015-09-11
AU2012335014A1 (en) 2014-06-19
CN104093454A (en) 2014-10-08

Similar Documents

Publication Publication Date Title
EA201491851A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EA201490053A1 (en) ANTIBODIES THAT ARE BIND OX40 AND THEIR APPLICATION
EA201190132A1 (en) HUMANIZED ANTIBODIES, CONNECTING CD19, AND THEIR APPLICATION
EA201270813A1 (en) ANTIBODIES TO N3pGlu BETA AMYLOID PEPTIDE AND THEIR APPLICATION
PE20181270A1 (en) ANTIBODY THAT NEUTRALIZES THE HUMAN SYNCITIAL RESPIRATORY VIRUS
EA201892793A1 (en) ANTI-HLA-G SPECIFIC ANTIBODIES
RU2014101707A (en) ANTI-Axl ANTIBODIES AND THEIR APPLICATION
ES2776179T3 (en) Antibodies directed against surface determinants of S. aureus
PE20190737A1 (en) ANTI-CD27 ANTIBODIES
PE20071055A1 (en) ANTI MN ANTIBODIES
PE20210377A1 (en) ANTI-PD-L1 ANTIBODIES AND USES OF THEM
UA117901C2 (en) Antibody variants and uses thereof
EA201591091A1 (en) Antigen-binding proteins for BCMA
EA201591153A1 (en) ANTIBODIES CONNECTING TL1A AND THEIR APPLICATION
EA200970879A1 (en) BINDING PROTEINS, INCLUDING ANTIBODIES, DERIVATIVE ANTIBODIES AND ANTIBODY FRAGMENTS, WHICH SPECIFICALLY BINDS TO CD154, AND THEIR APPLICATIONS
EA201291243A1 (en) ANTIBODIES AGAINST RESPIRATORY-SYNCTIAL VIRUS (RSV) AND METHODS OF THEIR APPLICATION
PE20141433A1 (en) NEUTRALIZING ANTIBODIES OF HUMAN CYTOMEGALOVIRUS
PE20120475A1 (en) SPECIFIC ANTIBODIES FOR DKK-1
NZ701444A (en) Antibodies to matrix metalloproteinase 9
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
CR20120027A (en) POLYPEPTIDES AND TREATMENT METHOD
EA201490677A1 (en) BONDING ANTIGEN CD27L PROTEINS
EA200970694A1 (en) PEHYLATED Fab ANTIBODY FRAGMENTS TO Aβ PEPTIDE
UA113623C2 (en) TISSUE FACTOR FACTOR (TFPI) MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR
RU2017129721A (en) ANTIBODIES AGAINST αβTCR